^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:BPI-361175 (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

    Excerpt:
    ...- Patients with histologically or cytologically confirmed diagnosis of inoperable locally advanced or recurrent/metastatic non-small cell lung cancer (NSCLC) with EGFR sensitive mutations....
    Trial ID:
    NCT05329298
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    5462 - BPI-361175, a 4th generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC)

    Published date:
    03/09/2022
    Excerpt:
    In vivo, oral administration of BPI-361175 led to tumor suppression and regression in multiple EGFR mutant models...In conclusion, BPI-361175 is a potent, selective, and orally bioavailable 4th generation EGFR-TKI which can potentially be used to treat NSCLC resistant mutations as well as at front line.